Author

Qinghong Han

AntiCancer (United States)

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Cancer Biology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Research Focus:drug response / drug discovery· 1 Approach:experimental assay· 1 Organism:human· 1

Frequent Co-Authors

Byung Mo KangiD· 1 shared Hiroaki KimuraiD· 1 shared Hiroyuki Tsuchiya· 1 shared Katsuhiro HayashiiD· 1 shared Kentaro IgarashiiD· 1 shared KOHEI MIZUTA· 1 shared Michael BouvetiD· 1 shared Norio YamamotoiD· 1 shared

Activity by Year

2025-2025 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 45 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

1 shared paperCancer Biology

Byung Mo KangORCID

Mutual co-authors in cluster

Author profile →

1 paper

Recent·Most cited

Human fibrosarcoma cells selected for very-high doxorubicin resistance, acquire trabectedin and eribulin cross-resistance, remain sensitive to recombinant methioninase, and have increased c-MYC expression

Sei Morinaga, Qinghong Han, KOHEI MIZUTA, Byung Mo Kang, Michael Bouvet, Norio Yamamoto, Katsuhiro Hayashi, Hiroaki Kimura, Shinji Miwa, Kentaro Igarashi, Takashi Higuchi, Hiroyuki Tsuchiya, Satoru Demura, Robert M. Hoffman

This study shows that doxorubicin-resistant fibrosarcoma cells are cross-resistant to trabectedin and eribulin but remain sensitive to recombinant methioninase, with increased c-MYC expression.

Frontiers in Oncology · Dec 8, 2025Peer-reviewedCancer Biology